AC
TBPH icon

Allstate Corporation’s Theravance Biopharma TBPH Stock Holding History

Allstate Corporation’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-14,681
Closed -$213K – 719
2021
Q2 		$213K Buy
14,681
+123
+0.8% +$2.31K 0.01% 703
2021
Q1 		$297K Buy
14,558
+2,151
+17% +$40.9K 0.01% 661
2020
Q4 		$220K Buy
+12,407
New +$223K 0.01% 683
2020
Q2 		– Sell
-9,434
Closed -$218K – 710
2020
Q1 		$218K Buy
+9,434
New +$236K 0.01% 577

Other funds holding TBPH

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

Allstate Corporation's TBPH Position: Q3 2021 in Review

Allstate Corporation sold out of Theravance Biopharma (TBPH) in Q3 2021, closing a stake of 14,681 shares — an estimated $213K sold.

Allstate Corporation first reported a position in TBPH in Q1 2020 and held it in 4 quarters. The position peaked at $297K in Q1 2021. 119 funds tracked by Wall St. Rank hold TBPH as of Q3 2021.

  • Allstate Corporation reported no remaining Theravance Biopharma position as of Q3 2021 after selling out during the quarter.
  • Allstate Corporation sold 14,681 Theravance Biopharma shares in Q3 2021, an estimated $213K.
  • Allstate Corporation first reported a position in Theravance Biopharma in Q1 2020 and held it in 4 quarters.
  • Allstate Corporation's Theravance Biopharma position peaked at $297K in Q1 2021.
  • 119 funds tracked by Wall St. Rank held Theravance Biopharma as of Q3 2021.

Based on Allstate Corporation's 13F filing for Q3 2021, filed 15 Nov 2021.